Celltrion Reports Results of CT-P10 (rituximab, biosimilar) in P-III for Advance Follicular Lymphoma (AFL)

 Celltrion Reports Results of CT-P10 (rituximab, biosimilar) in P-III for Advance Follicular Lymphoma (AFL)

Celltrion Reports Results of CT-P10 (rituximab, biosimilar) in P-III for Advance Follicular Lymphoma (AFL)

Shots:

  • The study involves assessing efficacy and safety of CT-P10 vs Rituxan (rituximab) in 140 patients in ratio (1:1) with AFL for a duration of two years
  • P-III study results: @ 2 Year OS (93.2% vs 95.3%); PFS (75.2% vs 73.5%); relapse or disease progression (19.4% vs 21.3%); well tolerated and safe, Presented at ASH 2018
  • CT-P10 (rituximab, biosimilar) is a mAb for targeting CD20 cells and is approved in EU for NHL, chronic lymphocytic leukemia, RA, granulomatosis with polyangiitis and microscopic polyangiitis

Click here to read full press release/ article | Ref: Celltrion | Image: Celltrion

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post